76471-50-6

Basic information

• Product Name: [(1R)-2-(4-iodophenyl)-1-methylethyl]amine
• Synonyms: [(1R)-2-(4-iodophenyl)-1-methylethyl]amine
• CAS NO: 76471-50-6
• Molecular Weight: 261.105
• Mol File: 76471-50-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: [(1R)-2-(4-iodophenyl)-1-methylethyl]amine(CAS DataBase Reference)
• NIST Chemistry Reference: [(1R)-2-(4-iodophenyl)-1-methylethyl]amine(76471-50-6)
• EPA Substance Registry System: [(1R)-2-(4-iodophenyl)-1-methylethyl]amine(76471-50-6)

Safety Data

• Hazardous Substances Data: 76471-50-6(Hazardous Substances Data)

Upstream product

• 14383-60-9 (R)-(-)-N-acetyl-α-methylphenylethylamine 
• 133906-31-7 (R)-(-)-N-(trifluoroacetyl)-1-(4-nitrophenyl)-2-aminopropane 
• 133867-98-8 (R)-(+)-N-(trifluoroacetyl)-1-(4-aminophenyl)-2-aminopropane 
• 133795-93-4 (R)-4-Nitroamphetamine 
• 156-34-3 l-amphetamine 
• 477260-03-0 2,2,2-trifluoro-N-[(1R)-2-(4-iodophenyl)-1-methylethyl]acetamide 
• 82691-32-5 Iofetamine hydrochloride 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 
• 21905-93-1 4-Iod-β-nitro-propenylbenzol 
• 21906-36-5 1-(4-iodophenyl)-2-propanone 

Downstream Products

• 699015-99-1 (1R)-1-(3-chlorophenyl)-2-{[(1R)-2-(4-iodophenyl)-1-methylethyl]amino}ethanol 
• 643093-80-5 tert-butyl [(2R)-2-(6-chloro-3-pyridinyl)-2-hydroxyethyl][(1R)-2-(4-iodophenyl)-1-methylethyl]carbamate 

Relevant articles and documents

N-isopropyl-p-iodoamphetamine hydrochloride is predominantly metabolized by CYP2C19

[123I]N-Isopropyl-p-iodoamphetamine hydrochloride ([ 123I]IMP) is clinically used to evaluate blood flow in the brain on single photon emission-computed tomography. This is a rare radiopharmaceutical that undergoes metabolism. The first step is reported to be [ 123I]p-iodoamphetamine formation. The drug-metabolizing enzyme(s) involved remain(s) unclear. This study examined the roles of human cytochrome P450 (P450) in the metabolism of nonradiolabeled IMP with the use of human liver microsomes (HLM) and recombinant human CYP1A1, -1A2, -1B1, -2A6, -2B6, -2C8, -2C9, -2C19, -2D6, -2E1, -3A4, and -3A5. Disappearance of IMP was examined because p-iodoamphetamine was not available. IMP (0.5 μM) time-dependently disappeared when HLM and NADPH-generating system were added to the reaction mixture. (S)-Mephenytoin (1 mM) inhibited the IMP disappearance by approximately 90%. The disappearance of IMP was predominantly catalyzed by recombinant CYP2C19, with Km and Vmax of 8.6 μM and 9.7 nmol · min-1 · nmol P450-1, respectively. IMP disappearance in CYP2C19-deficient HLM (CYP2C19*2/*2) was approximately 30% of that in the presence of HLM harboring wild-type CYP2C19, indicating that IMP is polymorphically metabolized by CYP2C19. High-performance liquid chromatography of the incubation mixture of IMP and CYP2C19 revealed an unidentified peak. As the area of the IMP peak decreased, the area of this unidentified peak increased in a time-dependent fashion. The peak was also detectable on incubation of IMP with HLM. Mass spectrometry revealed that the molecular weight of a compound in this unidentified peak was the same as that of p-iodoamphetamine. Thus, we demonstrated that IMP was predominantly metabolized by CYP2C19 to form p-iodoamphetamine. Copyright

AMINOALCOHOL DERIVATIVES

The present invention relates to a compound formula [I]: wherein Y is bond,--O--(CH2)n--(in which n is 1, 2, 3 or 4), etc., Z is cyano, tetrazolyl, etc., R1 is hydrogen, lower alkyl, etc., R2 is hydrogen or an amino protective group, R3 is hydrogen or lower alkyl, R4 is hydrogen or lower alkyl, R5 and R8 are each independently hydrogen, halogen, hydroxy, lower alkyl, etc., R6 is hydrogen, lower alkyl, etc., R9 is hydrogen or lower alkyl, and i is 1 or 2, or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.

AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS

The present invention relates to a compound formula [I] or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of pollakiurea or urinary incontinence.